Introduction
In the cystic fibrosis (CF) community, there is a need to focus on developing and evaluating endpoints for clinical trials in early disease. The European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) has established a Standardisation Committee consisting of researchers with expertise in specific outcome measures. The Standardisation Committee is undertaking a rigorous evaluation of potential outcome measures for multicentre clinical trials in CF. This article summarises the group's work on lung clearance index (LCI).
A full description of the classification of outcome measures is provided in the first document in the series of articles from the ECFS-CTN Standardisation Committee (CFTR biomarkers group) [1] . Briefly, outcome measures fall into three classes: clinical endpoints, surrogate endpoints and biomarkers. Clinical endpoints reflect how a patient feels, functions or survives and detect a tangible benefit for the patient [2, 3] . A surrogate endpoint is a laboratory measurement used to predict the efficacy of therapy when direct measurement of clinical effect is not feasible or practical. Ideally, surrogate endpoints should shorten the period of follow-up required. The link between the surrogate endpoint and long-term prognosis must be proven. Forced expiratory volume in one second (FEV 1 ) is still the only accepted surrogate outcome for the European Medicines Agency (EMA) and the North American Food and Drug Association (FDA). A biomarker is defined as "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic response to a therapeutic intervention". Biomarkers are mainly used to explore proof-of-concept for a specific compound. Some are currently being considered for "promotion" to the status of surrogate endpoint. Progression of lung disease in CF has slowed down [4] , and therefore FEV 1 has become a less sensitive outcome measure. LCI has repeatedly been shown to be superior to FEV 1 to monitor early CF lung disease when FEV 1 is within normal ranges [5, 6] . It thus appears a good candidate to become a new surrogate outcome measure in trials focusing on the early stages of disease. LCI may also be useful clinically to monitor patients with FEV 1 within normal ranges, however this article focuses on the use of LCI in clinical trials.
To gain acceptance of researchers and licensing bodies, an endpoint must however have a body of supporting evidence including acceptable clinimetric properties (Table 1 ) such as reliability, validity and responsiveness to treatment, and sufficient feasibility and safety. Clinimetric properties and feasibility are population and situation dependent, therefore data cannot readily be extrapolated to the CF population from other disease populations.
The aims of this project were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with cystic fibrosis, 2) to gain consensus of the group on the feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status.
Methods
An exhaustive literature search was conducted in MEDLINE, Allied and Complementary Medicine (AMED) and Embase using the following combination of keywords: ("lung clearance index" or "LCI" or "multiple breath washout" or "MBW" or "ventilation inhomogeneity" or "sulphur hexafluoride" or "SF6" or "nitrogen washout" or "helium washout" or "inert gas washout") and "cystic fibrosis". The search was limited to full text articles in the English language, with no limits on year of publication. A bibliography search was also conducted of all included articles and relevant reviews published until April 2013.
For clinimetric properties, data were extracted and tabulated for reliability, validity, correlation with other outcome measures, responsiveness and reference values. Definitions are given in Table 1 .
To evaluate feasibility, data were extracted and tabulated on the proportion of attempts that were successful and reasons for excluding tests. An expert panel also discussed the following topics and reached consensus on each: risk involved, cost, ease of performance, ease of administration, time to administer, equipment and space needed and applicable age group. Specific advantages and limitations of infant pulmonary function were also discussed.
Narrative answers to 4 key questions were discussed by the expert panel during several face to face meetings 1) Does LCI have the potential to become a surrogate outcome?;
2) For what kind of therapeutic trial is LCI appropriate? (therapeutic aim, phase of trial, target population, number of patients involved, number of sites involved); 3) Within what timeline can change be expected and what treatment effect can be considered clinically significant?; 4) What are the most needed studies to further define LCI in patients with CF and to explore its potential as a surrogate marker? The consensus of the group is presented in the current article.
After preparatory work over a period of 6 months, participants with expertise in multiple breath washout met to discuss and develop consensus on the four key questions and feasibility (November 17 and 18, 2010, and June 9, 2011). The manuscript was developed which reports both the systematic review of clinimetric properties (performed by the core writing team (LK, KDB, IS, PR)) and the expert panel's discussions (four key questions and feasibility). This resulted in a draft manuscript which was circulated to the group for review and revision until group consensus was achieved.
Results

Use of LCI in clinical trials in CF
LCI derived from a multiple breath washout (MBW) provides a global measurement of ventilation inhomogeneity. It reflects abnormalities in ventilation in the respiratory tract compared to normal, including the small airways which are affected early in CF lung disease and where changes are not easily detected with traditional pulmonary function techniques such as spirometry [7] . The ability to identify early airway dysfunction in these "silent years", when FEV 1 is often within normal range, is of great importance for investigating new therapies in infants and young children and in those with mild disease [8] . LCI is beginning to be used as an efficacy endpoint in CF clinical trials. It was the primary outcome in a recent phase 2, multicentre trial of ivacaftor in patients with the G551D mutation and normal lung function [9] . It was used in single centre interventional studies of rhDNase and hypertonic saline in infants and children with CF [10] [11] [12] . It is one of the major secondary efficacy measures in the ongoing UK CF Gene Therapy Consortium's large, placebo controlled, multidose trial of non-viral gene therapy (http://clinicaltrials.gov NCT01621867).
LCI is derived from a MBW technique which can be performed either with inhalation of an inert tracer gas such as sulphur hexafluoride (SF 6 ) or helium, or by using 100% oxygen to wash out resident nitrogen. The latter technique has been available for several decades, takes slightly less time to perform and is gaining increasing attention [13] . In the case of an exogenous tracer, the gas is inspired until equilibrium is reached (i.e. concentration of tracer is equal in both inhaled and exhaled air). At this point the tracer gas source is removed and the individual breathes room air until the concentration of the tracer gas in exhaled air is 1/40th of the equilibrium concentration, an arbitrary concentration based on the lower limits of detection of the early nitrogen analysers. In the case of using nitrogen Gustafsson [26] (ERJ)
Non-CF Children washout, which is a resident gas, 100% oxygen is delivered until mean expired nitrogen concentration falls below 1/40th of the original concentration. In both methods, LCI is calculated as the cumulative expired volume during the washout phase divided by the functional residual capacity (FRC) i.e. the number of FRC volume turnovers required to clear the tracer gas. FRC is derived from the cumulative exhaled marker gas concentration divided by the difference in end-tidal gas concentration at the start of the washout and the end-tidal concentration at the end of the washout. Individuals with greater ventilation inhomogeneity use a greater number of turnovers to clear the tracer gas and therefore will have a higher (more abnormal) LCI. Many different systems have been or are being used to measure MBW in clinical trials in CF. For detailed guidelines about washout equipment specifications, test performance and data analysis we refer to a recent ERS/ATS consensus document [14] . Although the mass spectrometer is considered the gold standard gas analyser equipment, it is very expensive, custom built for MBW and therefore not suitable for widespread use [14] . The majority of published results to date are calculated by offline analysis using proprietary software. The use of the software requires training and there is an element of subjectivity in reading the results. For LCI to be used as an outcome measure in large-scale multicentre trials, it is necessary to implement a file transfer and central reading facility. Only with such measures can variability be reduced. Commercially available systems, compliant with the above ERS guidelines will provide the opportunity to standardise the procedure in future multicentre trials. The online Table E1 lists the currently commercially available apparatuses and some of their characteristics. Results from MBW tests using different gases are not interchangeable, e.g. on average, LCI determined by nitrogen washout is higher than LCI determined by washout of SF 6 [15] . Traditionally, the mean of 3 (or at least 2) valid LCI measurements with FRC not differing more than 10% have been reported. The recent ERS document describes acceptability criteria in great detail [14] . If all other criteria are met, the new advice is to only reject tests where FRC differs by N 25% from the median values across the 3 tests. Most published studies pre-date this advice and have used a 10% criterion. Throughout the tables we will refer to the apparatus used to obtain the MBW measurements. Since most of the reported studies predate the ERS consensus, all necessary information is not always available.
Clinimetric properties of LCI
Reliability (Table E2 online)
The majority of studies on reliability were conducted in children, with fewer in infants and adults. In most reports, the mean coefficient of variation (CV) for LCI measurements within one session was low (between 3 and 7%) but the range was higher. A mean CV above 10% was reported in a study in children with CF using an Innocor with a closed circuit. Therefore this apparatus set-up is not recommended [14] . Both CV and ICC of measurements within one session were as acceptable in CF as in healthy controls. One study showed neither a significant nor systematic difference in LCI between repeated sessions of LCI measurements. A low variability between repeated sessions of LCI measurements has also been reported by others: mean CV of up to 9 % in the short and medium term and high intra-class correlation coefficients.
Validity (Table 2)
Overall, 22 out of 23 studies demonstrated the ability of LCI to discriminate between individuals with CF and healthy, non-CF subjects. Of these, 3 studies included adults only [16] [17] [18] , the others included either children and adults (n = 2) [19, 20] , or children only (n = 18 studies including 4 studies also in infants [21] [22] [23] [24] ). Several studies demonstrated the ability of LCI to discriminate between groups of patients with CF and differing degrees of lung disease based on age, infection status or structural changes on high resolution computerized tomography (HRCT) of the chest. In this respect LCI is superior to FEV 1 . In infants and children, six studies compared the sensitivity of LCI and FEV 1 as indicators of structural lung abnormalities demonstrating that for bronchiectasis and air trapping on HRCT, LCI is more sensitive but less specific than FEV 1 [22, [25] [26] [27] [28] [29] .
Correlation with other outcomes (Table 3)
Twenty one studies have examined the relationship between LCI and other outcome measures with the majority of studies focusing on FEV 1 and HRCT. In 10 studies in children and/or adults with CF, a significant but variable correlation between LCI and FEV 1 /FEV 0.5 was demonstrated [16] [17] [18] 20, 21, [29] [30] [31] [32] [33] . One study in preschool children reported a correlation with FEV 0.5 , FEF and sR aw . These studies also pointed out that LCI is superior in detecting abnormalities. In infants with CF diagnosed via newborn screening (mean age 11 weeks) there was no correlation between LCI and FEV 0.5 [21] . In a mixed group of infants and toddlers (including two with CF), LCI correlated with the volume of trapped gas (expressed as percent of FRC) [34] . Abnormal LCI was shown to have a moderate to strong correlation with structural abnormalities evaluated separately or using global HRCT scores. Overall, correlation was good between LCI and bronchial wall thickening, mucus plugging and bronchiectasis, but weaker with air trapping. LCI was also shown to correlate with other outcome measures including, age, onset of infection, type of infection, inflammation measured in the bronchoalveolar lavage fluid, blood gas analysis, exhaled nitric oxide fraction, capnographic parameters, and symptom score. (Table E3) One study demonstrated the validity of LCI in preschool children as a predictive test of abnormal lung function at an early school age. Whilst positive predictive values for future abnormalities were also good for FEV 1 , LCI had a stronger negative predictive value [35] . Further studies to investigate the relationship between LCI measurements and the long term course of CF (lung function, exacerbations etc.) are urgently required.
Predictive validity
Responsiveness (Table 4)
Several studies provide information on responsiveness of LCI in small numbers of patients (range n = 11 to 38). In patients with CF, LCI was able to detect a treatment effect after four weeks of [32] (Pediatr Pulmonol) FEV 1 /FVC z-score R = − 0.44, p = 0.003 FEF 
In preschool children with CF, LCI correlates with FEV 0.5 , FEF and sR aw 30 CF Children 2-5 yrs Mass spectrometer SF 6 sR aw r 2 = − 0.14, p = 0.04 Linear regression Aurora [8] (AJRCCM) FEV 0.5 r 2 = 0.21, p = 0.01 FEF r 2 = 0.28, p = 0.003
In infants with CF detected after newborn screening, LCI did not correlate with FEV 0.5 71 CF Infants after NBS Mean age 11 wks
Mass spectrometer SF 6 FEV 0.5 NS Pearson correlation coefficient Hoo [21] In a mixed group of infants and toddlers (including 2CF), LCI correlated with the proportion of trapped gas 8 inhalation of dornase alpha [10] , four weeks of inhalation of hypertonic saline [11] and after a course of intravenous antibiotics for a respiratory exacerbation [10, 11, 36, 37] . One short term study did not show a statistically significant treatment effect with 5 mg of inhaled salbutamol as measured by LCI in 11 children and adults with CF. Only S acin improved, an index derived from MBW which reflects inhomogeneity in the airways close to or within the gas exchange zone [19] . It may not be surprising that LCI did not detect change; bronchodilators target larger airways whereas LCI is considered to be more reflective of ventilation homogeneity in smaller airways. There is also little information on the efficacy of inhaled bronchodilator therapy in CF using other outcome measures.
Reference values (Table 5)
Reported reference values predate the ERS guideline. We list the reported reference ranges according to gas used, set-up used and age category. It is important to note that reference values are dependent on age of participants, method of analysis (i.e. online vs. offline), software used, device and set-up and tracer gas used. Reference values are not interchangeable between different methods. In addition, we refer to an abstract containing reference values for commercially available equipment over a wide age range [38] . (Table E4) Feasibility data were collated from studies in CF, and are mainly from children; fewer studies have been conducted in adults or infants. In children, success rates ranged from 24% to 100%. The study with the lowest success rates was evaluating feasibility in the clinical setting in which strict time constraints were imposed (20 min for participant familiarisation and performance of measurement). This is not as relevant in clinical trials as there tends to be more time for participant familiarisation and performance of repeat measures [32] . In infants and preschool children, success rate can be lower. Common reasons for exclusion of tests include manoeuvres that are not technically acceptable (e.g. unstable breathing pattern) or lack of within-session reproducibility (i.e. no two curves within 10% for FRC measurement). The experience of several hundred LCI measurements in adults with CF in the UK CF Gene Therapy Consortium gene therapy studies indicates feasibility in this group of close to 100% (unpublished observations).
Feasibility of LCI
Group consensus on feasibility
MBW is a safe technique since it uses either oxygen for nitrogen washout or very low concentrations of inert tracer gases SF 6 and helium.
For young children, quiet breathing is performed using a face mask, whereas for older children and adults, a mouth piece is used. In neonates the test can be attempted during natural sleep. This is usually impossible beyond the neonatal period.
Few have embarked on LCI measurements in children under the age of three years, especially beyond the newborn period. From experience with other lung function tests, it is anticipated that the test duration and the need for regular and quiet breathing will imply sedation. As for any test done under sedation this requires close monitoring and is associated with a small risk. In infants with rapid breathing rates, the gas analyser must have a rapid response time. Commercial stand alone SF 6 analysers can be adapted to provide the rapid response times necessary to measure LCI in infants. Most studies in infants have used a mass spectrometer. The nitrogen washout technique has not yet been validated in infants in whom the impact of breathing 100% oxygen on ventilation pattern should be further explored.
In infants and preschoolers, MBW is simpler than forced expiratory techniques. MBW requires only quiet tidal breathing whereas the raised volume rapid thoraco-abdominal compression (RVRTC) technique requires high skill, long term and continuous training and numerous acceptability criteria. RVRTC feasibility in infants has a much lower feasibility than LCI when comparing the percent of successful measurements (albeit between studies). A large multicentre trial evaluating feasibility in RVRTC also showed that feasibility was much lower in naive centres compared to more experienced ones, demonstrating the dependence on training and experience [67] .
MBW takes more time than routine spirometry. In general, three repeat measurements are performed to generate a single mean value. In healthy subjects, both phases take approximately less than 5 min. Both wash-in and wash-out require less time in healthy subjects than in people with obstructive airways disease. The time needed increases relative to the increase of LCI. The nitrogen wash-out technique has the advantage of being shorter, as a wash-in is not needed before the 1st washout. The time the patient is attached to the equipment is also reduced since all wash-in phases are done with room air. Time requirements also increase when off-line analysis is used, however automated calculation of LCI from the MBW tracer helps to reduce analysis time. The manpower required increases when testing infants and young children, as at least two people are needed.
The equipment (hardware and software) and consumables required depend on the technique used [14] . In general the following should be considered; a trolley-mounted analyser or mass spectrometer, space for the tracer gas cylinder, a seat for the individual, a TV/DVD for distraction and a computer with software for data storage and analysis. These can easily be accommodated in most lung function laboratories. Tracer gas build-up in confined spaces should be prevented by good ventilation of the test room. In multicentre studies, the tracer gas used must be approved by all national authorities, which may limit the use of SF 6 .
Ongoing developments may further improve LCI feasibility; assessing whether results from partial washout (first breaths) predict the 'standard' LCI value. The additional value of other indices derived from MBW, such as S acin and S cond , that describe the site of ventilation inhomogeneity, are being explored.
3.4. The "four key questions" 3.4.1. Question 1: Does LCI have the potential to become a surrogate outcome parameter?
LCI is potentially very valuable as a surrogate outcome parameter. It reflects disease in the peripheral airways which occurs early in CF lung disease and is not detected with traditional spirometric measures such as FEV 1 . LCI has a significant and growing evidence base which indicates that its clinimetric properties are positive and more useful than traditional spirometric parameters in early or mild disease. LCI has a well-established and acceptable safety and feasibility profile throughout the spectrum of ages and severities of CF lung disease. The test performance has been standardised in a recent ERS/ATS guideline [14] . The use of LCI in multicentre clinical trials will be facilitated in the near future by the standardisation efforts such as those by the ECFS-CTN Standardisation Committee: agreed standard operating procedures for performance of the measurement and for training and certification procedures, central quality control and the availability of central over-reading. The availability of commercial systems and systems that do not require specific gases such as SF 6 may also boost more general use and facilitate standardisation between centres in large scale trials.
Question 2:
For what kind of therapeutic trial is LCI appropriate? (therapeutic aim; phase of trial, target population, number of patients involved, number of sites involved) At present LCI has mainly been used in phase two trials evaluating therapeutic benefit. A recent phase two trial of ivacaftor in patients with mild lung disease showed that LCI was more responsive to treatment than FEV 1 [9] . A post-hoc power analysis demonstrated a much lower number of patients needed when using LCI rather than FEV 1 as primary outcome. Since this was a multicentre trial, it also demonstrates the feasibility of using LCI across centres in different countries. The accumulating evidence indicates that, in addition to phase two trials, LCI is becoming applicable to phase three trials. Given LCI's greater sensitivity than FEV 1 , it is especially appropriate for use in phase three trials in small populations (e.g. rare mutations), young children, patients with mild lung disease, or to reduce the number of subjects needed.
Question 3: Within what timeline can change be expected and what treatment effect can be considered clinically significant?
Available studies have not addressed how quickly LCI changes after an intervention. The biological mechanisms underlying abnormally raised LCI are thought to be (a) regional airway endoluminal obstruction by retained secretions, (b) regional airway obstruction due to mucosal airway inflammation and (c) regional remodelling/fibrosis/destruction of airways. Mechanisms (a) and (b) are amenable to change over days and improvements in LCI following treatment of acute CF exacerbations have been documented. A raised LCI might also have an irreversible part related to structural abnormalities (c).
The treatment effect that can be considered clinically significant should be larger than the difference in LCI seen between repeat measurements without intervention or change in clinical status. In healthy children and using SF 6 as inert gas and mass spectrometer as analyser, the CoR was 0.74 or 11% of the baseline value [39] . When using nitrogen washout and a commercial set-up, CoR was 0.6 in healthy children and 0.96 in children with CF [32] . For more data on test repeatability we refer to Table E2 .
Question 4:
What studies are needed to further define LCI in CF patients and its potential as a surrogate marker?
1. Clinical relevance: variability of LCI in preschool children and infants. Correlation of LCI with clinical outcome parameters such as time to pulmonary exacerbation. Use of LCI in a multicentre setting to study treatment benefit in preschool children and infants. Longitudinal evolution from birth in a large cohort of CF patients. 2. Methodology: further comparisons of LCI measured according to the recent consensus but using the different possible set-ups; normative ranges and CoR across ages and for all techniques. 3. Additional information compared to other outcome parameters: correlation with regional ventilation abnormalities as defined by imaging (e.g. hyperpolarized helium). Ideally these studies should be interventional (e.g. before and after treatment). Further correlations with inflammatory markers in bronchoalveolar lavage or/and sera.
Conclusion
This document provides an overview of the work of the ECFS-CTN Standardisation Committee on LCI. A systematic review of the clinimetric properties of LCI demonstrates its reliability, validity and responsiveness. LCI also has an attractive feasibility profile. It is particularly useful for multicentre trials in young children with CF and in patients with early or mild CF lung disease when FEV 1 is within normal range. This is the first article to collate the literature on LCI and CF in this manner and provides a strong evidence base to support the use of LCI in clinical trials in CF.
